The United Kingdom and the United States have forged a significant trade agreement that will preserve no import taxes on UK pharmaceutical shipments entering the US market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has pledged to raise spending on medicines through the public health system. This pledge guarantees that duties on these vital products will remain at nothing for a duration of the next three years.
This development is in response to previous warnings to dramatically increase import taxes on branded drug products, with potential rates discussed up to 100%.
"This arrangement with the United Kingdom reinforces the international landscape for cutting-edge drugs and establishes long-overdue fairness to American-British drug exports," an announcement declared.
Trade Importance
Drugs are one of the the United Kingdom's largest goods shipped to the US, which is easily the biggest buyer for major companies like GSK and AstraZeneca.
Trade data indicate that in the 12 months to the end of last September, the UK shipped medicines worth billions to the US. This figure made up 17.4% of British export trade in that period.
"This guarantee secures work, stimulates investment and facilitates the UK to become a international leader for medical research," the Business and Trade Secretary remarked.
Specific NHS Changes
The agreement involves several key commitments from the British government:
- Price Threshold Increase: The UK will increase the cost ceiling at which it judges new medicines to be prohibitively costly by 25%.
- Higher Drug Budget: There is a goal to raise total public funding on treatments from 0.3% of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The percentage drug companies must return to the NHS to stay within budget will be restricted at fifteen percent. Last year, refunds topped 20%.
Recent Tensions
This agreement comes amid a ongoing dispute between the pharmaceutical industry and the ministers over drug pricing and NHS adoption.
This friction were intensified by assertions that US patients were paying a premium for the identical medicines than people in the Britain and the EU.
In recent months, several significant pharmaceutical investments in the UK have been delayed or abandoned, while major funding commitments have been directed toward US facilities.
One official acknowledged that the NHS had to invest a greater share on medicines, noting that its spending on drugs had declined as a proportion of its overall budget over the last ten years.